Ascentage Pharma Group International - Unsponsored ADR AAPG
14.86
(0.37)
(2.43%)
as of 25 Sep
- Market cap
- $1.4B
- P/E
- —
Follow AAPG
| Jun '26 | Dec '25 | Jun '25 | Dec '24 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
1.22 | 1.79 | 1.54 | 1.26 |
+2 more quarters Free account |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
64.63% | 49.95% | 56.34% | 63.74% | |
Debt/Equity |
3.70 | 1.48 | 2.54 | 6.09 | |
Asset Turnover |
0.00 | 0.00 | — | — | |
Operating CF/Net income |
0.00 | 0.00 | — | 0.00 | |
Capex/Depreciation |
0.00 | (0.36) | — | (0.30) | |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.03 | 0.04 | |
Free Cash Flow per Share |
0.00 | 0.00 | — | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(87.41) | (171.84) | — | (18.58) | |
Working Capital |
60.39 | 186.01 | 93.45 | 42.13 | |
Capital Expenditures |
(1.75) | (3.94) | — | (3.33) | |
Net Current Asset Value |
(56.24) | 45.02 | (64.42) | (119.12) | |
| Other line items | |||||
Quick Ratio |
1.09 | 1.66 | 1.40 | 1.15 | |
Operating CF per Share |
0.00 | 0.00 | — | 0.00 | |
Capex per Share |
0.00 | 0.00 | — | 0.00 | |
Average Receivables |
62.68 | 28.12 | — | — | |
Average Payables |
13.59 | 12.62 | — | — | |
Average Inventory |
5.48 | 3.16 | — | — | |
Average Assets |
452.58 | 455.42 | — | — | |
Average Common Equity |
95.12 | 100.25 | — | — | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 |
Columns are period end dates